The Japanese drugmaker has continued to build momentum around antibody-drug conjugates (ADCs) and, in 2026, entered a collaboration with Shanghai-based ATLATL Innovation Center to source regional technologies and deepen its Asia-Pacific innovation network
Peptides provide complementary mechanisms without replacing proven therapies
Frequency: Once per day (subcutaneous), preferably at bedtime
Cellular Proliferation: Given IGF-1s role in promoting cellular proliferation and survival, long-term safety factors include possible effects on cell growth in many tissues
Contact: Errol Zhou (Mr.) Tel: +86-551-65523315 Mobile/WhatsApp: +86 17705606359 QQ: 196299583 Skype: [email protected] Email: [email protected] Add: 1002, Huanmao Building, No.105, Mengcheng Road, Hefei City, 230061, China Eli Lilly recently announced that detailed results of the Phase 3 SURPASS-4 (NCT03730662) clinical trial evaluating the dual-acting GIP and GLP-1 receptor agonist tirzepatide (LY3298176) for the treatment of type 2 diabetes have been published in top international medical journals "The Lancet" (The Lancet)
If youre ready to take a serious, science-backed approach to weight loss, schedule a free consultation at your local Gameday Mens Health clinic to see if GLP-1 medications are right for you.